ArticleScience translational medicine2026

Kras G12C- and G12D-driven lung cancers differ in oncogenic potency, immunogenicity, and relapse after Kras inhibition in mouse models.

Hai-Cheng Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.